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Abstract
Macrophage activation syndrome (MAS) has been reported in
association with many rheumatic diseases, most commonly in
systemic juvenile rheumatoid arthritis (sJRA). Clinically, MAS is
similar to hemophagocytic lymphohistiocytosis (HLH), a genetic
disorder with absent or depressed natural killer (NK) function.
We have previously reported that, as in HLH, patients with MAS
have profoundly decreased NK activity, suggesting that this
abnormality might be relevant to the pathogenesis of the
syndrome. Here we examined the extent of NK dysfunction
across the spectrum of diseases that comprise juvenile
rheumatoid arthritis (JRA). Peripheral blood mononuclear cells
(PBMC) were collected from patients with pauciarticular (n = 4),
polyarticular (n = 16), and systemic (n = 20) forms of JRA. NK
cytolytic activity was measured after co-incubation of PBMC
with the NK-sensitive K562 cell line. NK cells (CD56+/T cell
receptor [TCR]-αβ-), NK T cells (CD56+/TCR-αβ+), and CD8+ T
cells were also assessed for perforin and granzyme B
expression by flow cytometry. Overall, NK cytolytic activity was
significantly lower in patients with sJRA than in other JRA
patients and controls. In a subgroup of patients with
predominantly sJRA, NK cell activity was profoundly decreased:
in 10 of 20 patients with sJRA and in only 1 of 20 patients with
other JRA, levels of NK activity were below two standard
deviations of pediatric controls (P = 0.002). Some decrease in
perforin expression in NK cells and cytotoxic T lymphocytes was
seen in patients within each of the JRA groups with no
statistically significant differences. There was a profound
decrease in the proportion of circulating CD56bright NK cells in
three sJRA patients, a pattern similar to that previously observed
in MAS and HLH. In conclusion, a subgroup of patients with JRA
who have not yet had an episode of MAS showed decreased NK
function and an absence of circulating CD56bright population,
similar to the abnormalities observed in patients with MAS and
HLH. This phenomenon was particularly common in the
systemic form of JRA, a clinical entity strongly associated with
MAS.
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Introduction
The term 'macrophage activation syndrome' (MAS) in pedi-
atric rheumatology refers to a set of symptoms caused by
the excessive activation and proliferation of T cells and well-
differentiated macrophages [1-4]. This activation leads to
an overwhelming inflammatory reaction that can be fatal.
The pathognomonic features of this syndrome are found in
bone marrow aspirates: numerous, well-differentiated mac-
rophages (or histiocytes) actively phagocytosing hemat-
opoietic elements. Although MAS has been increasingly
recognized in association with almost any rheumatic dis-
ease, it is by far most common in the systemic form of juve-
nile rheumatoid arthritis (JRA) [1,5-11].
Clinically, MAS has strong similarities to familial hemo-
phagocytic lymphohistiocytosis (FHLH) and virus-associ-
ated or reactive hemophagocytic lymphohistiocytosis
(HLH) [2-4]. The immune abnormalities in the familial form
of HLH have been studied extensively, and the most con-
sistent finding has been global impairment of cytotoxicR30
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R31lymphocyte and natural killer (NK) cell function [12-14]. In
about 50% of patients with FHLH in North America, these
immunologic abnormalities are secondary to mutations in
the gene encoding perforin, a protein that mediates the
cytotoxic activity of NK and T cells [15]. Although it has
been proposed that abnormal cytotoxic cells might fail to
provide appropriate apoptotic signals for the removal of
activated macrophages and T-cells after infection is
cleared [16], the exact pathways that would link the
decreased NK and cytotoxic T cell function with macro-
phage expansion have not been confirmed.
We have previously reported that, as in HLH, NK function
is profoundly depressed in the vast majority of patients with
MAS [17] suggesting that this immunologic abnormality
might be relevant to the pathogenesis of the syndrome. In
the present study we sought to assess the extent of NK
dysfunction in the most common rheumatic disease of
childhood, JRA.
JRA is a chronic, idiopathic, inflammatory disorder with
diverse clinical symptoms both at onset and during the
course of the disease. Classification of this heterogeneous
disease has been based primarily on the type of onset,
namely the clinical manifestations during the first six
months [18,19]. There are at least three major onset types:
pauciarticular (four or fewer joints involved), polyarticular
(five or more joints), and systemic. The systemic onset form,
with its markedly febrile presentation, is certainly the most
distinct clinical subtype of the disease. In contrast to
patients with pauciarticular and polyarticular JRA, in whom
the joint disease usually overshadows the more general
symptomatology, in systemic onset JRA extra-articular fea-
tures such as spiking fevers, evanescent macular rash,
hepatosplenomegaly, lymphadenopathy, and, occasionally,
polyserositis are most prominent [20]. The reason for the
increased incidence of MAS in patients with systemic
forms of JRA in comparison with other clinical forms of this
disease is not clear, but NK cell abnormalities might have a
role [3]. The main purpose of this cross-sectional study was
to characterize numbers of circulating NK cells, their cyto-
lytic activity, CD56bright : CD56dim subset ratio, and per-
forin/granzyme B expression in the major cytotoxic cell
populations in patients with different clinical forms of JRA.
Materials and methods
Patients
In all patients included in the study, the diagnosis of JRA
was established on the basis of the American College of
Rheumatology (ACR) diagnostic criteria [18]. The main
clinical characteristics of the patients are summarized in
Table 1. Peripheral blood samples were collected from the
patients after obtaining informed consent under an
institutional review board-approved study of JRA.
Flow cytometric analysis
Relative and absolute numbers of NK, CD8+, and NK T
cells, as well as perforin and granzyme B expression in
these cell populations, were determined as described pre-
viously [14,21]. In brief, whole blood samples were first sur-
face stained with the following antibodies: fluorescein
isothiocyanate-labelled T cell receptor (TCR)-αβ, CD8-
peridinin chlorophyll protein (CD8-PerCP) (BD
Immunocytometry Systems, San Jose, CA), and CD56-allo-
phycocyanin (CD56-APC) (Immunotech, Brea, CA). Red
cells were then lysed with FACSlyse (BD Immunocytometry
Table 1
Clinical characteristics of patients with juvenile rheumatoid arthritis
Parameter Systemic onset JRA (n = 20) Polyarticular JRA (n = 16) or pauciarticular JRA (n = 4)
Male/female 9/11 14/6
Mean age, years (range) 11.5 (2–23) 12.8 (3–22)
Mean disease duration, years (range) 4.1 (0.2–16) 5.8 (0.9–15)
No. with active arthritis (%) 17 (85) 17 (85)
No. with active systemic disease (%) 8 (40) -
Mean ESR, mm/h (range) 30 (5–85) 21 (5–57)
No. (%) receiving
Prednisone 6 (30) 3 (15)
Methotrexate 12 (60) 10 (50)
TNF-blocking agent 3 (15) 5 (25)
Intra-articular steroids 1 (5) 4 (20)
NSAID 17 (85) 18 (90)
ESR, erythrocyte sedimentation rate; JRA, juvenile rheumatoid arthritis; NSAID, non-steroidal anti-inflammatory drugs; TNF, tumor necrosis factor.
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R32Systems) and washed. The resultant white cell pellets were
then fixed and permeabilized with Cytofix/Cytoperm (BD
Pharmingen, San Diego, CA) and stained with either phy-
coerythrin-conjugated mouse IgG2b anti-perforin or phyco-
erythrin-conjugated mouse IgG1 anti-granzyme B
antibodies (BD Pharmingen). After being washed, cells
were resuspended in 1% paraformaldehyde and stored at
4°C until analyzed with a FACSCalibur flow cytometer
(Becton Dickinson, San Jose, CA). The following gates
were used to distinguish the three populations of interest:
CD8+ T cells were defined as being TCR-αβ+, CD8+, and
CD56-; NK cells as TCR-αβ- and CD56+; and NK T cells as
TCR-αβ+ and CD56+. All populations were also restricted
to a live cell gate based on forward versus side scatter. The
perforin-positive or granzyme B-positive regions were set
by using isotype-matched negative control samples, and
the percentage positive for each gate was reported.
NK cell cytotoxicity analysis
NK activity was assessed after co-incubation of peripheral
blood mononuclear cell preparations (effector cells) with
51Cr-labeled target cells at various effector : target cell
ratios as described previously [21]. The NK-sensitive K562
line was used as a source of target cells. The levels of radi-
oactivity released from target cells into supernatants were
assessed by gamma scintillation after 4 hours of incuba-
tion. All experiments were performed in triplicate in a 96-
well microtiter plate. Spontaneous and maximum release
wells were included on each plate as controls. Spontane-
ous release was assessed in the wells containing 51Cr-
labeled target cells in medium without effector cells. Maxi-
mum release was determined in the wells containing
labeled target cells in the presence of detergent to promote
total lysis. The percentage lysis was calculated as
described previously [21]: percentage lysis = 100 × (mean
radioactivity of sample minus mean radioactivity of back-
ground)/(mean maximum radioactivity minus mean radioac-
tivity of background).
Lytic units were calculated from the curve of the percent-
age lysis. One lytic unit was defined as the number of effec-
tor cells needed to produce 10% lysis of 103 target cells
during the 4 hours of incubation.
Controls
The results were compared with the normal ranges for age-
matched controls that have been developed in our clinical
laboratory by studying 41 pediatric samples obtained from
the out-patient clinic during routine 'well-child' visits from
children considered 'healthy' [14].
Statistical analysis
The unpaired t-test and Wilcoxon two-sample test were
used to compare NK cytolytic activity and perforin/
granzyme B expression between the patient and control
groups. The rank correlation test was used to characterize
the relationship between NK cell activity and perforin
expression. The unpaired t-test and logistic regression
analysis were used to assess the possible contribution of
treatment regimens to the development of NK cell
dysfunction.
Results
NK cell cytolytic activity and NK cell numbers
As shown in Fig. 1, some decrease in NK cell cytolytic
activity was noted in both clinical groups of JRA patients.
This trend was particularly strong in patients with systemic
JRA (sJRA). The mean cytolytic activity in the sJRA group
was 4.0 (SEM = 1.2) compared with 8.2 (SEM = 1.6) in
patients with pauciarticular/polyarticular JRA (unpaired t-
test, P = 0.042; Wilcoxon two-sample test, P = 0.0062).
Furthermore, in a subgroup of patients with sJRA, NK cell
function was profoundly depressed. Thus, in 10 of 20
patients with sJRA and in only 1 of 20 patients with pauci-
articular/polyarticular JRA, the NK cell cytolytic activity was
below two standard deviations (SD) of the control group
(χ2, P = 0.002). The same degree of NK cell dysfunction
was observed in our previous studies of patients with MAS
and HLH [17].
As shown in Table 1, a significant proportion of the patients
studied were on immunosuppressive medications, includ-
Figure 1
NK cell cytolytic activity in patients with juvenile rheumatoid arthritis (JRA)
(JRA). Activity of NK cells was determined after co-incubation of periph-
eral blood mononuclear cells with the NK-sensitive K562 cell line and 
expressed in cytolytic units (LU, y-axis). NK activity values in 20 patients 
with systemic JRA, 20 patients with other subtypes of JRA and 41 
healthy children are shown as dots. The difference between results for 
patients with systemic JRA and other JRA is statistically significant (Wil-
coxon two-sample test, P = 0.0062). For comparison, mean ± 2SD val-
ues determined in healthy individuals are shown as horizontal lines.
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R33ing prednisone, methotrexate, and tumor necrosis factor
(TNF)-blocking agents. Because NK function can be
affected by such medications [22], we sought to assess
whether the differences in treatment regimens between
patients with sJRA and pauciarticular/polyarticular JRA
might have contributed to the observed differences in NK
function. Overall, patients receiving immunosuppressive
drugs had somewhat lower levels of NK cytolytic activity.
However, logistic regression analysis showed no statisti-
cally significant differences in NK function between
patients with or without immunosuppressive treatment
(independent variables: prednisone, methotrexate, and
TNF-blocking agents; dependent variable NK cytolytic
activity below 2SD of control samples, χ2 = 0.877, P =
0.831).
Because low NK cell numbers in patients with sJRA have
been previously noted in one study [23], we assessed
whether the decrease in NK cell cytolytic activity might
have been related to low NK cell counts. A moderate corre-
lation between NK function and the proportion of peripheral
blood mononuclear cells that were NK cells was found for
both groups of patients with JRA (r = 0.52, 95% confi-
dence interval 0.08–0.8 in the sJRA group; r = 0.47, 95%
confidence interval 0.7–0.75 in the other JRA group). Cor-
relation coefficients between function and number of NK
cells were not significantly different between the two JRA
groups (Fisher's Z transformation; P = 0.7). The mean
number of NK cells (expressed as a proportion of TCR-αβ-
/CD56+ cells in a population of peripheral blood mononu-
clear cells) among the sJRA group was 0.077 (SD 0.04) in
comparison with 0.081 (SD 0.034) among the other JRA
group was not significantly different (P = 0.72 on the basis
of the two-tailed independent t-test). Thus, it seems that
suppressed NK function is not simply a result of reduced
numbers of NK cells among patients with sJRA.
CD56dim and CD56bright NK cells
On the basis of on the intensity of CD56 staining, human
NK cells have been recently subdivided into two distinct
subsets with distinct functional characteristics. CD56bright
NK cells have the ability to produce high levels of immu-
noregulatory cytokines, in particular interferon (IFN)-γ, but
are in general poorly cytotoxic (reviewed in [24]). By con-
trast, CD56dim NK cells produce relatively low levels of
cytokines and are potent cytotoxic effector cells expressing
high levels of peforin. We have previously described a lack
of the circulating CD56bright NK cells in patients with MAS
and HLH [25]. The analysis of the fluorescence-activated
cell sorting data in the current study revealed that three
patients with sJRA had a similar abnormality, namely an
almost complete absence of circulating CD56bright cells.
Figure 2 shows examples of CD56 staining in such
patients.
Perforin expression
Because reduced perforin expression in cytotoxic effector
cells has previously been reported in sJRA [26,27], we
assessed perforin content and relative proportions of
perforin-positive NK cells, CD8+ lymphocytes, and NK T
cells. High variability was noted in both groups of patients
with JRA. The comparison of the mean values between
patients with sJRA versus other JRA groups did not reveal
statistically significant differences. However, the examina-
tion of individual patterns of perforin staining in NK cells
revealed mean channel fluorescence (MCF) values below
2SD of the control group in seven patients, five of whom
had sJRA. In addition to low MCF, one of these patients
with sJRA had profoundly decreased proportions of per-
forin-positive cells in all three cytotoxic cell populations, a
pattern that we have previously described in patients with
sJRA who have had multiple episodes of MAS [17]. Exam-
ples of such abnormal patterns of perforin expression are
shown in Fig. 3. In contrast, the patterns of staining for
granzyme B were similar between patients and controls in
all three cytotoxic cell populations (data not shown).
Because perforin is a protein that mediates the cytotoxic
activity of NK cells, we assessed whether decreased per-
forin expression might have contributed to the development
of NK dysfunction in JRA. In the group of seven patients
with low perforin levels in NK cells, only three had NK cyto-
lytic activity below 2SD of the control group. Furthermore,
there was no significant correlation between MCF in NK
cells and their cytolytic activity (r = 0.1596 for patients with
sJRA, and r = 0.1991 for patients with other JRA subtypes).
Discussion
In this study, profoundly depressed NK cell activity was
observed in a large subgroup of patients with sJRA and in
only 1 of 20 patients with the polyarticular form of the dis-
ease. The extent of NK dysfunction in this group of patients
was similar to that seen in patients with MAS [17] or HLH
[12,13]. The two study groups (sJRA versus other JRA sub-
types) were well matched in terms of age, duration of the
disease, and treatment regimens with the exception of a
slightly higher proportion of patients with sJRA receiving
steroids. Steroids have been reported to suppress the
cytolytic activity of NK cells [22], and this might potentially
have contributed to the observed differences in NK func-
tion. However, the logistic regression analysis did not show
significant differences between groups defined on the
basis of treatment regimens. In addition, several patients
with sJRA who demonstrated profoundly depressed NK
cell cytolytic activity were receiving only non-steroidal anti-
inflammatory drugs. Owing to the limitations of the statisti-
cal power with the numbers of study subjects enrolled, it is
possible that some effects of the immunosuppressive med-
ications might have been underestimated. Nevertheless,
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sJRA that is intrinsic to the disease itself.
Further analysis of the flow cytometry data revealed that
some of the patients with sJRA had a rather selective dis-
appearance of the circulating immunoregulatory CD56bright
subset of NK cells, a pattern previously seen in patients
with MAS or HLH [25]. These cells express low levels of
perforin and are, in general, poorly cytotoxic [24]. The
disappearance of CD56bright NK cells from peripheral circu-
lation is therefore unlikely to account for the defects in cyto-
lytic activity of NK cells. In contrast, CD56bright NK cells
might have a function in regulating the CD56dim perforin-
bright cells, and in this case their disappearance might have
an effect on cytolytic activity in some sJRA patients. Alter-
natively, the apparent absence of immunoregulatory NK
cells in peripheral circulation might reflect their active
recruitment to sites of inflammation.
Although the observed NK dysfunction in a subgroup of
patients with sJRA might not be of primary etiological sig-
nificance for JRA itself, the similarities to the immunologic
abnormalities seen in MAS and HLH suggest that
depressed NK cell activity is likely to be relevant to the
pathogenesis of MAS in sJRA. It is important to mention
that low NK cell activity has been noted in many rheumatic
diseases [28], most notably in systemic lupus erythemato-
sus [29]. In our study, however, in a subgroup of patients
with sJRA, the extent of NK dysfunction was profound, with
an almost complete absence of cytolytic activity. This par-
allels the fact that, although MAS has been described in
association with almost any rheumatic disease and it is not
uncommon in systemic lupus erythematosus [30], it is by
far most common in sJRA [4-11].
Other groups have noted low levels of perforin expression
in cytotoxic cells from patients with sJRA in comparison
with other clinical forms of the disease, suggesting that this
feature might be responsible for the increased incidence of
MAS [26,27]. In our study, when patients with sJRA were
analyzed as a group, perforin levels were not significantly
different from those in patients with other JRA types. How-
ever, the examination of the individual patterns of perforin
staining revealed a small subgroup of JRA patients with a
very low perforin content in NK cells. Most of these patients
had sJRA. Furthermore, one of them had profoundly
decreased proportions of perforin-positive cells in all three
major cytotoxic cell populations, a pattern that has been
previously reported in patients with MAS [17] and in the
carriers of perforin-deficient FHLH [14]. Although no over-
all correlation between perforin expression and NK cell
cytolytic activty was noted in our study, we still cannot
exclude the possibility that, at least in some patients,
reduced perforin expression might have functional signifi-
cance. In other words, there might be some heterogeneity
in the mechanisms underlying NK cell dysfunction in sJRA.
The existence of such heterogeneity was also noted in our
previous study of MAS patients [17] that included ethni-
cally diverse Caucasian, African American, and Latin Amer-
ican patients. The ethnic heterogeneity of the patients with
JRA included in this study might also underlie the discrep-
ancy between our results and the study by Wulffraat and
colleagues [26], which showed that patients with sJRA as
a group had lower perforin expression in cytotoxic effector
lymphocytes. That study included a much more ethnically
homogeneous population of Dutch children.
Granzyme B is another important component of the per-
forin-mediated cytotoxicity pathway. In our study both
Figure 2
Flow cytometric analysis of CD56bright and CD56dim natural killer cells. (a) In healthy individuals, most circulating NK cells are CD56dim (about 90%) 
and express high levels of perforin. In contrast, CD56bright NK cells comprise about 10% of all human NK cells and express low levels of perforin. (b, 
c) Two distinct patterns of CD56 staining observed in patients with systemic juvenile rheumatoid arthritis (sJRA): (b) normal pattern (observed in 17 
of 20 patients with sJRA as well as in all controls, and all other JRA patients); (c) almost complete disappearance of CD56bright subset of NK cells 
(observed in 3 of 20 patients with sJRA only).
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tinguishable from those seen in healthy controls, suggest-
ing that the observed NK dysfunction is not likely to be
related to abnormal granzyme B expression.
The cytolytic activity of NK cells in our study was measured
by using NK-sensitive K562 cells, which are lymphoblasts
derived from a patient with chronic myelogenous leukemia.
The exact receptors involved in the NK-mediated lysis of
K562 cells have not yet been identified. However, the lysis
of some similar cell lines has been recently shown to be
mediated through the natural cytotoxicity receptors
(NKp46, NKp30, and NKp44) [31]. These receptors have
important biologic functions in the innate immune system,
and their abnormal expression might have a function in the
development of NK dysfunction in sJRA.
On the basis of our data, the feature that distinguishes sys-
temic onset JRA from other forms of JRA, and is common
to the major hemophagocytic syndromes, is NK cell dys-
function. The exact mechanisms that would link deficient
NK cell function and, in some cases, depressed perforin
expression with the expansion of activated macrophages
are not clear. One possible explanation is that decreased
NK function might be responsible for a diminished ability to
clear the infecting pathogen and remove the source of anti-
genic stimulation at early stages of infection [32]. This
would lead to persistent antigen-driven T cell activation
associated with an increased production of cytokines, such
as IFN-γ and granulocyte/macrophage colony-stimulating
factor, that stimulate macrophages. Subsequently, the sus-
tained macrophage activation would result in tissue infiltra-
tion and in the production of high levels of TNF-α,
interleukin-1, and interleukin-6, which have a major role in
the various clinical symptoms and tissue damage.
Several recent studies using perforin-deficient and NKcell-
depleted mice indicate that NK cells and perforin-based
systems are also involved in the downregulation of immune
responses through a direct effect of NK cells and/or per-
forin-based systems on the survival of activated lym-
phocytes [33-36]. NK dysfunction might therefore lead to a
failure to provide homeostatic signals for the removal of
activated T cells. For instance, Su and colleagues [33]
demonstrated that the infection of NK-depleted mice with
murine CMV results in an exaggerated immune response
associated with more persistent expansion of cytotoxic
CD8+ T cells that secrete IFN-γ, an important macrophage
activator. Another possible explanation is related to the
recently discovered ability of NK cells to lyse autologous
antigen-presenting cells such as dendritic cells, thus limit-
ing the magnitude of an immune response [37]. Interest-
ingly, this interaction might involve the above-mentioned
natural cytotoxicity receptors [38].
Figure 3
Flow cytometric analysis of perforin expression in NK cells and cyto-toxic CD8+ cells
toxic CD8+ cells. (a) Normal control: 95% of NK cells and 14% of 
CD8+ cells are perforin-positive. (b) A patient with systemic juvenile 
rheumatoid arthritis (sJRA) with a normal pattern of perforin expression: 
normal mean channel fluorescence (MCF) in NK cells with 92% of NK 
cells and 10% of CD8+ T cells being perforin-positive (this pattern was 
observed in all controls, in 18 of 20 other JRA patients, and in 15 of 20 
sJRA patients). (c) A patient with sJRA with low MCF in NK cells and 
mildly decreased proportions of perforin-positive NK cells (74%) and 
CD8+ T lymphocytes (5%) (this pattern was observed in 2 of 20 other 
JRA patients and in 5 of 20 sJRA patients). (d) A patient with sJRA with 
low MCF in NK cells and very low proportions of perforin-positive NK 
cells (20%) and no perforin-positive CD8+ T lymphocytes (observed in 
1 of 20 sJRA patients only).
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NK cell dysfunction is the feature that distinguishes sys-
temic onset JRA from other forms of JRA, and is common
to the major hemophagocytic syndromes. This suggests
that impaired cytotoxic functions and/or deficiency of
immunoregulatory NK cells are relevant to the development
of MAS. Patients with sJRA who have these immunologic
abnormalities may therefore be a high-risk group that might
benefit from closer observation.
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